10 Best Guardant Health Alternatives & Competitors (2026)

Insilico Medicine applies generative AI for drug discovery and biomarker identification. Its platform accelerates target discovery in aging and oncology. Unlike Biocogniv it serves pharmaceutical R&D teams rather than routine clinical labs with milestone-based rather than SaaS pricing.

PathAI provides AI-powered pathology analysis for cancer diagnostics with strong partnerships in pharma trials. It excels in image-based detection with extensive validation datasets. Compared to Biocogniv it focuses more narrowly on tissue slides rather than blood-based predictions and typically uses project-based pricing instead of broad lab subscriptions.

Tempus builds precision medicine platforms combining clinical and molecular data at scale for oncology. Strengths include vast data networks and physician-facing tools. Versus Biocogniv it targets treatment selection over initial disease screening and operates at higher price points with enterprise contracts.

Aidoc delivers real-time radiology AI for urgent findings across CT and X-ray workflows. It integrates directly into PACS systems with high sensitivity. In comparison to Biocogniv it serves imaging departments rather than general labs and emphasizes always-on triage over longitudinal risk scoring.

Zebra Medical Vision offers automated imaging analytics for population health and incidental findings. It supports multiple modalities with cloud deployment. Relative to Biocogniv it leans toward radiology use cases and often provides per-study pricing models suitable for varying volumes.

Paige develops computational pathology software for prostate and breast cancer detection from slides. It features strong regulatory clearances in multiple markets. Compared with Biocogniv it remains specialized in digital pathology workflows and offers tiered licensing for hospital networks.

Owkin combines federated learning with multimodal data for oncology and immunology research. Strengths lie in privacy-preserving collaborations across institutions. Against Biocogniv it targets academic and translational research rather than day-to-day lab operations with grant or partnership funding models.

Freenome focuses on multi-omics liquid biopsy for early cancer detection using machine learning. It emphasizes non-invasive screening tests. In contrast to Biocogniv it develops its own assays rather than analyzing third-party lab results and follows a diagnostics-as-a-service approach.

GRAIL develops multi-cancer early detection blood tests powered by machine learning on large-scale datasets. It prioritizes population screening programs. Compared to Biocogniv it operates as a test provider with centralized processing rather than an embeddable analytics platform for existing labs.